NCCN Guidelines Insights: Central Nervous System Cancers, Version 2.2022. Journal of the National Comprehensive Cancer Network : JNCCN Horbinski, C., Nabors, L. B., Portnow, J., Baehring, J., Bhatia, A., Bloch, O., Brem, S., Butowski, N., Cannon, D. M., Chao, S., Chheda, M. G., Fabiano, A. J., Forsyth, P., Gigilio, P., Hattangadi-Gluth, J., Holdhoff, M., Junck, L., Kaley, T., Merrell, R., Mrugala, M. M., Nagpal, S., Nedzi, L. A., Nevel, K., Nghiemphu, P. L., Parney, I., Patel, T. R., Peters, K., Puduvalli, V. K., Rockhill, J., Rusthoven, C., Shonka, N., Swinnen, L. J., Weiss, S., Wen, P. Y., Willmarth, N. E., Bergman, M. A., Darlow, S. 2023; 21 (1): 12-20

Abstract

The NCCN Guidelines for Central Nervous System (CNS) Cancers focus on management of the following adult CNS cancers: glioma (WHO grade 1, WHO grade 2-3 oligodendroglioma [1p19q codeleted, IDH-mutant], WHO grade 2-4 IDH-mutant astrocytoma, WHO grade 4 glioblastoma), intracranial and spinal ependymomas, medulloblastoma, limited and extensive brain metastases, leptomeningeal metastases, non-AIDS-related primary CNS lymphomas, metastatic spine tumors, meningiomas, and primary spinal cord tumors. The information contained in the algorithms and principles of management sections in the NCCN Guidelines for CNS Cancers are designed to help clinicians navigate through the complex management of patients with CNS tumors. Several important principles guide surgical management and treatment with radiotherapy and systemic therapy for adults with brain tumors. The NCCN CNS Cancers Panel meets at least annually to review comments from reviewers within their institutions, examine relevant new data from publications and abstracts, and reevaluate and update their recommendations. These NCCN Guidelines Insights summarize the panel's most recent recommendations regarding molecular profiling of gliomas.

View details for DOI 10.6004/jnccn.2023.0002

View details for PubMedID 36634606